Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECTmeso platform trial in relapsed malignant mesothelioma
ISRCTN15046526Phase 2Completed
- Sponsor
- University of Southampton
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MRTX1719 and brigimadlin in mesothelioma (2 cohorts), sponsored by University of Southampton. Primary endpoint: Disease control rate at 12 weeks. Started Oct 2025; status: completed.
02
Drugs
MRTX1719brigimadlin
03
Conditions
mesothelioma
Beyond the preview
Go deeper on ISRCTN15046526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15046526.